Free Trial
NASDAQ:GLMD

Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis

Galmed Pharmaceuticals logo
$3.02 +0.14 (+4.86%)
(As of 11/12/2024 ET)

About Galmed Pharmaceuticals Stock (NASDAQ:GLMD)

Key Stats

Today's Range
$2.86
$3.18
50-Day Range
$2.81
$15.10
52-Week Range
$2.73
$23.80
Volume
63,044 shs
Average Volume
782,180 shs
Market Capitalization
$1.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Galmed Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
21st Percentile Overall Score

GLMD MarketRank™: 

Galmed Pharmaceuticals scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Galmed Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Galmed Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Galmed Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Galmed Pharmaceuticals has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Galmed Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    3.08% of the float of Galmed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Galmed Pharmaceuticals has recently increased by 73.86%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Galmed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Galmed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.08% of the float of Galmed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Galmed Pharmaceuticals has recently increased by 73.86%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Galmed Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Galmed Pharmaceuticals this week, compared to 0 articles on an average week.
  • Search Interest

    Only 2 people have searched for GLMD on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Galmed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -89% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.80% of the stock of Galmed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    76.14% of the stock of Galmed Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Galmed Pharmaceuticals' insider trading history.
Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Stock News Headlines

Galmed Pharmaceuticals Amends Equity Purchase Agreement
Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
See More Headlines

GLMD Stock Analysis - Frequently Asked Questions

Galmed Pharmaceuticals' stock was trading at $5.46 at the beginning of the year. Since then, GLMD stock has decreased by 44.7% and is now trading at $3.02.
View the best growth stocks for 2024 here
.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) issued its quarterly earnings results on Wednesday, August, 28th. The biopharmaceutical company reported $2.16 earnings per share (EPS) for the quarter.

Galmed Pharmaceuticals shares reverse split on Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galmed Pharmaceuticals investors own include Viking Therapeutics (VKTX), OPKO Health (OPK), SCYNEXIS (SCYX), Bristol-Myers Squibb (BMY), Plug Power (PLUG), Applied Genetic Technologies (AGTC) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
8/28/2024
Today
11/12/2024
Next Earnings (Estimated)
11/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GLMD
Employees
20
Year Founded
N/A

Profitability

Net Income
$-6,910,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$33.02 per share

Miscellaneous

Free Float
516,000
Market Cap
$1.87 million
Optionable
Not Optionable
Beta
0.80

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:GLMD) was last updated on 11/12/2024 by MarketBeat.com Staff
From Our Partners